ReviewMikrochimica acta2025
Fluorescent nanomaterials for early detection of cancer biomarkers: a review.
Review in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early cancer diagnosis has become one of the prominent challenges in recent years. Conventional diagnostic methods such as ultrasound, X-ray, bone scan, and computed tomography lack sensitivity for early-stage cancers and often involve high costs and invasive procedures. Therefore, identifying specific molecules indicative of cancer (biomarkers) is critical for early diagnosis and effective treatment planning. Fluorescent biosensors have emerged as a promising approach for early cancer detection, disease monitoring, and treatment management. The present review delves into the latest developments in nanomaterial-based fluorescent biosensors for cancer biomarker detection. It explores the potential of nanomaterials, including metal-based nanoparticles, up-conversion nanoparticles, quantum dots, carbon nanostructures, and luminescent metal-organic frameworks for sensor development. A performance evaluation of the biosensors based on key quality measures (such as detection limits, linear range, and efficiency) is also summarized. Finally, the review addresses the current challenges and future directions in overcoming technical hurdles in cancer diagnostics.
Indexed as
Identifiers
41272204What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.